IS8024A - Adamantanafleiður, aðferðir til að framleiða þær og lyfjablanda sem inniheldur þær - Google Patents

Adamantanafleiður, aðferðir til að framleiða þær og lyfjablanda sem inniheldur þær

Info

Publication number
IS8024A
IS8024A IS8024A IS8024A IS8024A IS 8024 A IS8024 A IS 8024A IS 8024 A IS8024 A IS 8024A IS 8024 A IS8024 A IS 8024A IS 8024 A IS8024 A IS 8024A
Authority
IS
Iceland
Prior art keywords
producing
methods
pharmaceutical compositions
compositions containing
adamantan
Prior art date
Application number
IS8024A
Other languages
English (en)
Inventor
Caffrey Moya
Ford Rhonan
Pimm Austen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8024A publication Critical patent/IS8024A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
    • C07C13/54—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings
    • C07C13/605—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system
    • C07C13/615—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system with an adamantane ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS8024A 2003-02-21 2005-09-14 Adamantanafleiður, aðferðir til að framleiða þær og lyfjablanda sem inniheldur þær IS8024A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300480A SE0300480D0 (sv) 2003-02-21 2003-02-21 Novel compounds
PCT/SE2004/000227 WO2004074224A1 (en) 2003-02-21 2004-02-19 Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them

Publications (1)

Publication Number Publication Date
IS8024A true IS8024A (is) 2005-09-14

Family

ID=20290476

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8024A IS8024A (is) 2003-02-21 2005-09-14 Adamantanafleiður, aðferðir til að framleiða þær og lyfjablanda sem inniheldur þær

Country Status (18)

Country Link
US (1) US7227038B2 (is)
EP (1) EP1599432A1 (is)
JP (1) JP2006518376A (is)
KR (1) KR20050101559A (is)
CN (1) CN100378047C (is)
AU (1) AU2004213356B2 (is)
BR (1) BRPI0407734A (is)
CA (1) CA2515434A1 (is)
CO (1) CO5580815A2 (is)
IL (1) IL169818A0 (is)
IS (1) IS8024A (is)
MX (1) MXPA05008690A (is)
NO (1) NO20054329L (is)
PL (1) PL378574A1 (is)
RU (1) RU2005123802A (is)
SE (1) SE0300480D0 (is)
WO (1) WO2004074224A1 (is)
ZA (1) ZA200506579B (is)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
EP1633401A1 (en) * 2003-05-29 2006-03-15 AstraZeneca AB A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
EP1644041A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
EA013904B1 (ru) 2003-12-18 2010-08-30 Янссен Фармацевтика Н.В. Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
CN101490060B (zh) 2006-07-13 2012-04-11 詹森药业有限公司 Mtki喹唑啉衍生物
TW200819416A (en) * 2006-09-05 2008-05-01 Astrazeneca Ab Novel process 470
JP5536647B2 (ja) 2007-07-27 2014-07-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピロロピリミジン
CN102046240B (zh) 2008-03-25 2014-06-25 阿费克蒂斯药品公司 新的p2x7r拮抗剂及其应用
KR20100053150A (ko) * 2008-11-12 2010-05-20 한국생명공학연구원 아릴옥시아세틸계 유도체를 유효성분으로 포함하는 ｄｎａ 메틸트렌스퍼레이즈 억제용 약학적 조성물
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
AU2011252351A1 (en) 2010-05-14 2012-10-11 Affectis Pharmaceuticals Ag Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2574840T3 (es) 2011-07-22 2016-06-22 Actelion Pharmaceuticals Ltd. Derivados de amidas heterocíclicas como antagonistas de receptores p2x7
WO2013108227A1 (en) 2012-01-20 2013-07-25 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
WO2014074995A1 (en) * 2012-11-09 2014-05-15 Scidose, Llc Enema composition for treatment of ulcerative colitis having long term stability
EA029644B1 (ru) 2012-12-12 2018-04-30 Идорсиа Фармасьютиклз Лтд Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
CA2891499C (en) 2012-12-18 2021-07-06 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
WO2014115078A1 (en) 2013-01-22 2014-07-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
EP2956135B1 (en) 2013-01-22 2016-11-16 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as p2x7 receptor antagonists

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
ATE197146T1 (de) 1993-08-10 2000-11-15 Black James Foundation Gastrin-und cck-rezeptorligande
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ZA988967B (en) 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CN1147483C (zh) 1999-04-09 2004-04-28 阿斯特拉曾尼卡有限公司 金刚烷衍生物
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
EP1397137B1 (en) 2001-05-25 2009-10-14 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
DE60209734T2 (de) * 2001-07-02 2006-08-31 Akzo Nobel N.V. Tetrahydrochinolin-derivate
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) 2003-02-18 2003-02-18 Astrazeneca Ab New combination
US20070281931A1 (en) 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
EP1644041A1 (en) 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
EP1633401A1 (en) 2003-05-29 2006-03-15 AstraZeneca AB A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha
SE0302192D0 (sv) 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Also Published As

Publication number Publication date
ZA200506579B (en) 2006-05-31
CN100378047C (zh) 2008-04-02
SE0300480D0 (sv) 2003-02-21
AU2004213356B2 (en) 2007-03-15
US7227038B2 (en) 2007-06-05
NO20054329D0 (no) 2005-09-20
EP1599432A1 (en) 2005-11-30
CN1751010A (zh) 2006-03-22
IL169818A0 (en) 2007-07-04
CO5580815A2 (es) 2005-11-30
MXPA05008690A (es) 2005-10-05
BRPI0407734A (pt) 2006-02-14
US20060160904A1 (en) 2006-07-20
NO20054329L (no) 2005-11-21
CA2515434A1 (en) 2004-09-02
KR20050101559A (ko) 2005-10-24
AU2004213356A1 (en) 2004-09-02
PL378574A1 (pl) 2006-05-02
JP2006518376A (ja) 2006-08-10
RU2005123802A (ru) 2006-02-27
WO2004074224A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
IS8024A (is) Adamantanafleiður, aðferðir til að framleiða þær og lyfjablanda sem inniheldur þær
IS7543A (is) Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær
IS7261A (is) N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær
IS2939B (is) Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar
IS7226A (is) Fjölbrigða form af rimonabant, framleiðsluaðferð og lyfjasamsetningar sem innihalda það
DK1913001T3 (da) (r)-n-methylnaltrexon, fremgangsmåder til syntese og farmaceutisk anvendelse heraf
DK1628547T3 (da) Oralt snusprodukt og fremgangsmåde til fremstilling deraf
IS7735A (is) Bensódíasepín afleiður og lyfjasamsetningar sem innihalda þær.
DK1490062T3 (da) Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
TWI340138B (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
IS7552A (is) Bensótengdar heteróarýl amíð afleiður af þíenópýridíni, gagnlegar sem meðferðarmiðlar, lyfjasamsetningar sem innihalda þær og aðferðir við notkun þeirra
IL171170A (en) History of itensinoids and their pharmaceutical preparations, methods of preparation and use thereof
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
IL173044A0 (en) Aryl and heteroaryl compounds, compositions, and methods of use
AU2003291668A8 (en) Sacrificial compositions, methods of use thereof, and methods of decomposition thereof
NO20054006D0 (no) Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer
PL380851A1 (pl) Nowe pochodne pirydynowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne
NO20050741D0 (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
DK1641832T3 (da) Fremgangsmåde til fremstilling af fiberholdig pektin og produkter og anvendelser heraf
NO20054711D0 (no) Fremgangsmater og farmasoytiske blandinger for palitelig oppnaelse av akseptable serum-testosteronnivaer
DE60333094D1 (de) Verbindungen, zusammensetzungen und verfahren
IL162201A (en) Radio-isotope conjugated compounds, pharmaceutical compositions comprising them, uses thereof and method of production thereof
EP1680109A4 (en) AMIDE DERIVATIVES AS ION CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE DERIVATIVES
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
DK1518827T3 (da) Krystalliseret IM-12-faststof og fremgangsmåde til fremstilling heraf